Dana E. Rathkopf

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

europeanurology.com Favicon

urotoday.com Favicon

ejcancer.com Favicon

onlinelibrary.wiley.com

Articles

First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf

Oct 1, 2024 | urotoday.com | Dana E. Rathkopf

Read the Full Video TranscriptOliver Sartor: Hi, I am Dr. Oliver Sartor with UroToday and delighted to be able to have a guest from Memorial Sloan Kettering, Dana Rathkopf, who's going to be talking about some very provocative data that she presented at ESMO 2024 in Barcelona. Dana is a professor at Memorial Sloan Kettering, and I'm delighted to have you here today, Dana. Dana Rathkopf: Thank you so much, Oliver, for having me.
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate-risk or high‐risk prostate cancer: Results of part 2 of a randomized phase

Jan 2, 2024 | acsjournals.onlinelibrary.wiley.com | Rana R. McKay |Wanling Xie |Xiaoyu Yang |Andres Acosta |Dana E. Rathkopf |Vincent P. Laudone | +9 more

CONFLICT OF INTEREST STATEMENT Rana R.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →